The Biggest Risk To ABA Might Be Perception: Autism Therapy Under the Microscope with Chris Larson (Part II)
1 hrAudio
Send us Fan Mail ABA on Tap is proud to present Chris Larson (Part 2 of 2): Private equity didn’t just “enter” ABA, it helped build the modern autism therapy industry as we know it and that reality comes with uncomfortable questions. Mike and Dan continue the brew with Chris Larson from Behavioral Health Business for part two, and we get specific about what investment capital changed at the macro level: access, scale, hiring, payer relationships, and the growth that followed insurance mandates. Then we turn the lens toward the hidden cost of speed, especially when investors expect a three to seven year arc and clinical care requires trust, continuity, and judgment. We talk through the ethical tension head-on. Chris breaks down why private equity firms answer to limited partners, why that mindset can clash with provider ethics, and why “McDonald’s ABA” is a real fear across the field. At the same time, we don’t let clinicians off the hook: nothing gets implemented without a BCBA green light, and the culture we teach new BCBAs can become the culture they assume is normal. That leads into workforce pipeline problems, the lack of a nursing-style university partnership model, and why the field keeps having to build its own training engine. From there, we move into the push for an ABA standard of care and why it keeps stalling, including iCHOM efforts and newer bets like Project Align and eye tracking technology. We also unpack the Maryland RBT strike and union vote, what “living wage” means when reimbursement rates are set by payers, and why RBT turnover hurts kids, families, and providers. We close by exploring collaboration with pediatricians, the limits of “objective” measurement in behavioral healthcare, and why opioid-crisis comparisons can mislead even when incentives rhyme. If you care about ABA therapy quality, reimbursement, RBT wages, BCBA ethics, and the future of autism services, hit play, then subscribe, share this with a colleague, and leave us a review. Tune in, Drink Up and ALWAYS ANALYZE RESPONSIBLY. Support the show 🔥 Enjoyed this episode? Don’t forget to subscribe, rate, and review on your favorite podcast platform! 📢 Connect with Us: 🔗 Website: https://abaontap.com 🎧 TikTok: https://www.tiktok.com/@aba.on.tap.podcast 📸 Instagram: https://www.instagram.com/abaontap/ 🎥 YouTube: https://www.youtube.com/@ABAonTap 💼 LinkedIn: https://www.linkedin.com/company/aba-on-tap 💡 Support the Show: ☕ Love what we do? Buy us a virtual drink! Support ABA on Tap 🎙️ Interested in sponsoring? Partner with us 🚀 Join the ABA on Tap Community! Stay updated on the latest episodes, live events, and exclusive content. 🎧 Analyze Responsibly & Keep the Conversation Going! 🍻
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_03Welcome to ABA on tech. A mic radio with Dan Lowry. So without further ado, sit back, relax, and always analyze responsibly. Hey, hey, welcome back to ABA on tap.
SPEAKER_03I am your ever-grateful co-host, Mike Rubio. We're talking private equity and many other things with the esteemed Chris Larson from Behavioral Health Business. This is part two. Enjoy.
SPEAKER_00No, thank you for sharing that. I I think that's that's super, super important. And also, private equity has the resources that can lobby and do things on a bigger scale. I think that's one of the biggest issues with ABA, everything's so siloed and everybody's competing against each other. There's no like unity or unionization with anything. And as a result of that, it's so fragmented. So yeah, there's definitely a lot of a lot of benefits there. Would you say, so you mentioned that for every one company that you see, you talked about card in the beginning, you know, kind of falling apart, that you see two or three or maybe even more thriving.
SPEAKER_00Would you say that private equity globally, not necessarily for the individual client, but on the macro scale, has had a net positive benefit for the ABA provider field as a whole?
SPEAKER_01For the industry, net positive, no doubt. Okay. Now, the degree to like it is a net positive. If we're just going to go in on a you know two-dimensional linear scale where scale we're at the middle of zero, neither positive nor negative, to like how negative or how positive. But I'm going to come down squarely on the side of net positive. The industry does not exist today. There's not enough interest, and there's no interest in it. There's no people going into this field. And again, the access that we have today cannot have could not have happened without the capital that private equity put into it.
unknownOkay.
SPEAKER_03So a lot of that comes with insurance mandates when we let the commercial product or they was they were mandated to provide reimbursement for our service specifically. I guess what that was done largely, I could I would argue, and this is debatable, by a parent movement led by very smart people with legal skills. Is that what it would take then? What what as providers, what influence do we have over now, given some of the false premises of rampant fraud and and so on?
SPEAKER_03We always, as a small outfit, we're always in conversation with payers and trying to kind of help them understand to whatever level they care how much influence they have over the quality of our care based on their payment. But maybe it's the consumer that has to come after this situation to make any change. I don't know if you've got any any thoughts on that.
SPEAKER_01I mean, yeah, I've got a couple. So to really kind of combat you know premises at the you know, at any level, it takes it takes two things. It takes uh it takes potent messengers and it takes time. Right. So like the state mandates, like we talk about them like as a kind of monolith and thing that happened all at once. No, that happened over the course of like 10 years. And it took the probably the most both vulnerable, but also I would say like the most effective and sympathetic messengers to get that done. And that is the stories of people who are impacted by whatever the issue is.
SPEAKER_01So autistic parents spent an incredible amount of time and put themselves into the absolutely brutal mix brutal arena that is public advocacy. So, I mean, that's not a specific recommendation or a solution to what you had presented, Mike, but that's how it worked in the past, and I don't really see any reason why it wouldn't work again in the future. Now, is the sympathetic and effective messenger parents in this instance? Is it the ABA providers that are trying to build you know inroads in their community? Maybe. You know, I I don't know what the answer is to that question, but you can always count on people of true passion and true means uh to get into whatever arena that they are called to.
SPEAKER_01And it's just maybe a matter of making the right connections and helping providing some organizing force to that.
unknownYeah. Yeah.
SPEAKER_03Thanks for your insight on that. Again, I I know I'm throwing out these very general premises because I know you you your knowledge, your experience is so layered in terms of business, and then inevitably, what does that look like with regard to practice to some extent? So again, I appreciate your very conscientious uh answers on these very broad uh questions I'm asking you.
SPEAKER_00I have one more question on the private equity piece, and I'm not at all pushing back on your perspective. I I appreciate it. I want to add addition to it or add maybe a caveat and get your thoughts on that. So I totally agree that private equity has had benefit in getting ABA's name out there and kind of on the macro scale as the field as a whole to where we are today. Private equity in general, to my understanding, and again, I think there's all sorts of different types of private equity. There's all sorts of different intentions and things like that.
SPEAKER_00I'm just kind of using it as a general term. In my experience with the ABA field, a lot of times we'll get in, we'll try to fix it, and then want to get out within, you know, three to seven years. That's kind of the general MO that we've seen. So it's more like short-term gain and we don't really care about the long-term stuff because we're just trying to get in and out. So if we can just get the numbers to where they need to be, then we can get out, make a profit, and get on. Don't care if it's ABA, don't care if we're making chalkboards or paninis at the store. Like the product doesn't really matter.
SPEAKER_00It's just the cash in versus cash out. Is it possible that while private equity has had benefit in the short term and getting us to where we are, that it runs the risk of the services because maybe they're more templated or more monetarily focused versus clinically focused. The services then get devalued, which means the field and the reputation of the field potentially gets devalued, which longer term might have a larger negative impact because then the field or the term ABA is like, oof, we don't want that stuff anymore.
SPEAKER_00Does is no one? What are your thoughts on that?
SPEAKER_01Yeah, nobody wants to see like the McDonald's a vication of ABA. So, yes, definitely see where you're coming from. And yes, private equity is a really short, has a really short view of the world. You know, respect how you respect how you will, if at all, you know, what their incentives are. They a private equity firm doesn't actually have any of its own money. Like none of the money that it gives or puts in that puts bets on it is its. Like a lot of the money that most private equity firms come from other like really big financial institutions, retirement funds. To some degree, it comes from like high worth individuals and things like that.
SPEAKER_01So their their obligation, their ethic is to the investors, the limited partners that they have in the funds that they that they pile up. And it in their moral calculation, they are obligated to try to take care of the resources that they have been entrusted with. Now, that is not the ethic that the provider has, or even the uh ABA provider corporation has. The ethic is completely different. So it's not shocking to me that there is a conflict between the ethics just on its face, like it shouldn't work. And it's it's kind of it's kind of remarkable that it works to what degree that it does work.
SPEAKER_01Now I will observe I will observe in conversations, and this isn't really like a direct, a direct like response to what what I'm sharing, Dan, is that when we're talking about the these negative impacts, the potential devaluing of the service because of the short time frame and the maybe the lack of interest that the investor will have in the clinical product, um, I actually hear that and I take to some degree the expect the expectation that BCBAs will then have the runway to do things on their terms.
SPEAKER_00Okay.
SPEAKER_01And nothing happens in the process of providing ABA without a green light from a BCBA. You know, the while while diagnostics might be different, no treatment plan is put together that can be then submitted for a reimbursement that wasn't put together by a BCBA. You know, who are the clinical directors that are that are getting hired by these private equity firms that might establish you know some questionable practices or practices that don't comport with one's personal ethic or like how they would do it? Well, those are BCBAs too, right?
SPEAKER_01So who are the people that are creating unironically, the people that are creating companies in like Indiana specifically, just because that's where the most dramatic examples are, that really worked the system when it came to the Medicaid 40% billing practice, they were BCBAs. So the point that I would that I would I would highlight there in when it comes to the structural issue is that there is also a structural responsibility that BCBAs have in making sure that those bad things don't happen. And at the same time, at least especially in the very beginnings of like very beginnings of private equity investment into the space, those BCBAs were they're doing all right.
SPEAKER_01Like AB ABA was not like invaded or like taken over by private equity, it was invited in. It knocked on the door, flashed a bunch of money in front of people, and said, Hey, would you like to walk away with this big sack of cash? Now, that practice is actually changing because what has been the most painful but most obvious lesson in investing in ABA over the last couple of years is that you can't do the stereotypical three to five years and then flip because and then like tell the CEO to go take a hike because you want to put your guy in there.
SPEAKER_01It won't work. The most powerful force within an organization that is highly that is highly ethical, that has you know standards and practices that have led it to both success financially, but also into building relationships with people is the CEO. And once you take away that dynamic, that mag that magnetic personality that kind of holds it all together, you've basically taken the keystone away from an arch. The whole thing's gonna fall apart. So, you know, while I'm I'm not gonna say like the structural issues that you're highlighting aren't gonna go away, they're always gonna be there.
SPEAKER_01And it's always gonna be this eternal tension to which you know the competing forces are gonna duke it out, both at the mic, at the macro level, but also in the individual company level to try to figure out who's gonna win out the day. I do have some hope that there has been enough pain uh from investors in this space that they'll continue to invest in it, they'll continue to grow it, but they'll take lessons learned and try to keep the people at the heart of the thing that make it work. Because if you don't, you're looking at wasting all of the all the money and wasting all the equity that you are tasked to try to grow as an investor.
SPEAKER_01So there's actually a lot, there actually are a lot of financial incentives toward ethical practice, in my observation. No, that makes I feel empowered.
SPEAKER_00Yes, that makes a lot of sense. And yeah, I I appreciate that. The concern I have with that is that a lot of BCAAs, I forget the number, are have been certified in the last like two to three years. Like it's uh you know an exponential field. And most, I don't know most, I think most of them are kind of done in-house, like it's an RBT or it's some staff that was like, okay, I like the field, and then that company puts them through their certification, and as a result, they maybe sign an agreement or something like that to stay within the that company for a period of time.
SPEAKER_00And so a lot of times they only necessarily know uh one way of doing things, and that very well because so many have been crowned recently or certified recently, might only be like the you know, the private equity way of doing things. And again, I I'm not trying to be disparaging of private equity, that's just one way of doing things. And I can just speak from my own experience that when business became more focused on, first of all, you have to be profitable to have a business, right? So I think that's also very important to say.
SPEAKER_00But when that became the primary focus, then it was all every clinical meeting that we ever had was always about maximizing your hours. How do you get more hours? How do you can this family do it then? How do we is it it was always like monetary and hours based, and and the clinical discussions left. So yeah, when the BCBAs are the ones signing off on the treatment plan, it does come down to them and it is their signature, absolutely, but maybe they don't know any different because maybe they've only been taught one way of doing things, or maybe they're just so stressed because you also mentioned the the monetary gain that private equities bought.
SPEAKER_00And when I hear what some of these BCBAs are making, like you're literally making more than we get reimbursed for the BCBA code. I have no idea how that even works. Like, you must be billing an insane amount of hours. So for them, they also maybe have a lifestyle that they're like, well, I don't want to push back on my employer at risk of losing this really high-paying job. So it is a little bit absolutely at the end of the day, it does come down to the person signing it, but maybe a little more nuanced and a little more variables in to why they might do that.
SPEAKER_00What are your thoughts on that, Chris?
SPEAKER_01Yeah, I mean, if if in the collective consciousness there's enough BCBAs that are willing to compromise on their values because of the paycheck they're getting, that's not a private equity problem. Yeah, that's a BCBA ethics problem. Yep.
SPEAKER_00That's a good point. Yeah.
SPEAKER_01I mean, that that being said, who's creating the conditions in which that morality gets played out? It is the private equity.
SPEAKER_00So the that's a good point you made. Thank you.
SPEAKER_01You guys originally uh set this up as like this is gonna be like a pub style conversation, but this is actually quite you know heady stuff. I don't know if this how many conversations like this are happening at pups, but sorry, just quick on the water. There we go. Yeah, I've got my water too. But to to to address to address the point directly, I think that there is a structural problem in the generation of BCBAs. I don't think the col I'll just call it the academy. I don't think universities have enough, either they have enough buy-in from their states. Maybe the industry in private equity doesn't hasn't invested enough in the the mutually beneficial relationship that a lot of industries have with the academy to generate people that can come out of these programs ready to hit the ground, both in terms of their competency, their skills, and also their know-how as a practitioner, right?
SPEAKER_01So, Dan, like one of the things like I don't I'm still I am still trying to grasp my head is just how much the autism therapy industry has to put into building its own workforce. That's kind of I think that that that kind of blows my mind. Like in in let's let's say nursing, it's not the same. Again, we're getting into the problem.
SPEAKER_03I think it's a good comparison.
SPEAKER_01It's the closest that I can get to you. So yeah, universities, like they they they do so much to create nurses and they have really tight relationships with their local trade colleges, with our local, you know, public four-year land grant, depending on how your state does it, the public universities, and there's a very strong pipeline there. But that is a pipeline that developed over the course of like a hundred years, right? And a lot of, and I mean a lot of the hospitals, unless they're you know completely like kind of new, they usually grow up alongside a university because universities have doctors, hospitals need doctors, right? We don't I don't see that, I don't see that relationship, that pipeline at play.
SPEAKER_01That's not a like a fault thing as much as it is this is a developmental assessment that needs to somehow, somehow get rectified and addressed. And I don't the only solution that I can put forward is that it's the it's the collective autism therapy industry's problem to solve. Maybe that is actually a key point of advocacy advocacy that needs to happen to where their states need to step up and they need to build much better pipelines into the field of BCBA. So like they universities have the resources to build the programs to where people coming out of school won't be so heavily influenced by the culture, the culture alone of the organizations that they're getting their and again, screw this word out, getting their practicum hours or getting their internship hours or training hours at observation hours.
SPEAKER_01Again, not a clinician, but I do know some things sometimes.
SPEAKER_00Well, no, I appreciate that. Oh, I'm sorry. I appreciate that. That was just real really enlightening, and I think you you boiled it down that it's not necessarily a private equity problem. If a BCBA is willing to sell out at the end of the day, it's a BCBA problem. And it's also a the field is an infancy problem, so there hasn't been an exact like you, you know, we are evidence-based and we do have articles, but a lot of them go back to 1985, and it's like, well, yeah, we can we can keep referencing that, but there, you know, we can all kind of pick and choose what evidence if you wanna if you want to do something, you can find the evidence to justify how you're gonna do it and still potentially be within what you think is your own personal ethics code, and doesn't deviate too far from BACB ethics code that would require any further discipline.
SPEAKER_00So, yeah, no, that's a really good point. I appreciate you bringing that up, Chris. Mike, I'll I'll pass it back to you.
SPEAKER_03Man, I'm trying to pick and choose where where I want to go next. So you we we talked a little bit about McDonald's, and that inevitably brings up a phrase like standard of care. I know you've spent some time looking at those efforts. I understand the effort from a medical perspective. I think we were talking about heart surgeons earlier, and or or certain uh certain surgeons can specify medical protocol to specific medical code, even indirect work can be reimbursed because of that.
SPEAKER_03There's a lot of strengths to that. We can certainly define our protocols and procedures, and then I like to think that ABA, if we were to compare it to surgery or like a heart surgeon, it's okay, we can define those protocols and procedures very strictly. But I'm gonna say that ABA, from a behavioral perspective, it's almost like the patient's heart isn't always gonna be in their chest, and we're gonna have to apply it at a certain heart rate and beat and barometric pressure, and there's so much more variability, which then makes that uh task of standardization a little bit challenging to say the least.
SPEAKER_03You've spent time and in your writing and your uh journalistic endeavors talking to people who are making very valiant, very noble efforts toward the standard of care in ABA. Let me pass that to you. Talk to us about those efforts, where you see them falling short, where you see people moving forward with great momentum and confidence.
SPEAKER_01Yeah, I in terms of the things that I cover that I feel like I can speak on the the most. This isn't this is definitely isn't one of them. Again, this is where I have a clear deficiency in blind spot because I'm not a clinician. Like I know I I'm able to understand the words that people tell me and I can put them together in ways that are correct and true to what I'm talking about. But like those are things that you know I'm I don't really know a ton about. But that being said, and there are many, many efforts that are you know that are underway right now to try to bring some level of standardization to care.
SPEAKER_01And what we're what the industry is running into is because of the infancy of the industry, there's not like a l there's not a ton to pull on when it comes to trying to consolidate practices at large. I mean, within just within the last, I want to say it was like two or three years ago, maybe three years ago, there was a group very there's a very large group of people that came up with you know standards for working within the context of insurance plans called iCHOM.
SPEAKER_01And they came up with actually two different types of protocols that could be give a back could could give a basis for some kind of universal language for both understanding like standard of care, but also translating that into what is valuable to measure in terms of relationships with payers. It went nowhere. And there are there's another kind of effort that's just getting started up that wants to lean into eye tracking technology as a more like kind of objective basis to understand and measure the core symptomology to then get a better and easier to translate at scale language for the progress that treatment is being made.
SPEAKER_01And then the the kind of the theory of the case is that by using something that the collective healthcare system sees as slightly more objective, i.e., a machine, to do a measurement of some aspect of one's biology, that that then would help self-organize towards some better ends with when it either comes to clinical practice or standard operating procedures within a company and then the arrangements that they have with payers. To just click down on that just a little bit more. So, like this specifically, I wrote about this thing called Project Align, where several very large providers are going to partner up with Early Point Health for their eye tracking technology that they think can give them a tool by which they can start to identify, you know, things that they've got going on in their clinics that will lead to some greater end that can give some degree of standardization to the industry.
SPEAKER_01But, you know, speaking at just to the subtlety of like what that should be, could be or what the options are. Again, not a clinician, I can't tell you.
SPEAKER_03Now that I think your answer was perfect, and that's exactly the type of information that we wouldn't necessarily hear on on the podcast that I think you're uniquely able to provide based on your work. So I really appreciate that. It's interesting how it becomes sort of a biometric, and I'm not opposed to it. I think that's fascinating. I think that's a nice entry. And then, well, for us, we're always working, not that eye tracking isn't behavioral, but we would be looking at some further collateral effect in terms of interacting with your environment now based on how your eyes might be scanning your environment, you know.
SPEAKER_03And we could boil that down to something like joint attention. So again, it's it's very interesting to think of like more of a social communicative behavioral approach that we take, knowing that. This medical field, we use the word biologic, you know, that yeah, that that would be the best way for us to give something as as quantifiable as we claim to be, that would be our best route. And and I don't know that we that we have a good analog. I don't know if you've got any comment on that. Now you you mentioned one that went nowhere, and I I hope the eye tracking thing goes somewhere.
SPEAKER_03And but maybe it's not that we have to reject that now. Maybe it's that we're gonna get a lot of these biological examples that that the medical field would do better with in terms of measurement as we figure out which ones actually have a behavioral collateral effect.
SPEAKER_01So I will be probably be speaking, you know, out of ignorance here, but like I don't I don't I'm not aware of or know of anything that right now exists that gives a great biological measure to a behavioral issue, right? So like the tracking thing is as close is as close as you're as you're gonna get. That's good. But it that kind of approach comes from a just honest to God effort try to bridge the gap between behavioral health and physical health care. And it's it is one. I would say like it's like again, on on like the two-dimensional scale of like how bad, how good is it?
SPEAKER_01I want to say it's like definitely on the this is probably a good attempt. Yeah, yeah, but to be to stand up for the industry a little bit, just because something is like measured by a machine doesn't necessarily make it necessarily like more valid to an assessment of health as opposed to observations from folks that are again, they're using the clipboards, but they're observing, and those measures have been validated by science. I mean, science is science, guys. Like, but for just the way that healthcare has has shaped out, if we can't measure it with a machine, we don't believe it.
SPEAKER_01I'm Mike, I want to go back to your your diabetes example. We have machines that tell us how much you know insulin or how much blood sugar, you know, whatever levels are again, not diabetic, luckily, and again, not a ton of people close to me, so I'm gonna screw up those phrases. And I'm so sorry for everybody that does have that part of your life that I don't know. I think your point is well preserved. There's no there's not a machine that you can plug in or that you can safely use that says this is how much autism you have. Right.
SPEAKER_00Yeah.
SPEAKER_01There's it just doesn't it doesn't exist, and it's not fair to the industry to be forced to that standard because of the because of the history and frankly, kind of maybe the hangups of physical healthcare, that if you can't observe it with a machine, like it's not real. Like I have a machine that measures my heart, my, you know, my my heartbeat and blood pressure. I've got a machine that can tell me the pressure in my eye, right? Like if I've got like a glaucoma or like the shape of my eye with astigmatism. There's not a machine that can do that in autism. And unfortunately, the industry is all the worse for it.
SPEAKER_01And it's not the industry's fault. It's just again, it just it's kind of the odd person out at the at the dinner table that is American healthcare.
SPEAKER_03Yeah, no, I and I love the example, and I and I I agree with you. I completely commend the effort because I think it is a technological, a prospective technological link, meaning that it could allow us to speak their language. And then I appreciate your other premise much more, which is I don't know that that exists. I I don't know either. I had the good fortune of of having a little bit of neuroscience and imaging research in my background, and we spent some time looking at the functional MRI premise in terms of looking at differences in the way brains activate for certain tasks, making somebody do a cognitive task in an MRI machine that I've been out of the fields for a little while, so I don't know if it's how much better it's gotten, but that's not a natural environment.
SPEAKER_03It's a pretty impossible task. It was, again, a noble effort, did really well for my master's thesis, but the application of it was clearly just research. It wasn't anywhere near, nor do I think it is anywhere near at this point, even though there's probably some multi-level marketing out there that would tell you differently.
SPEAKER_01But I don't know about multi-level marketing, but a while ago, when I say it might have been a year ago, there is a startup that is working on technology based out of the University of Louisville, funnily enough, that says that it can correctly diagnose autism at a rate of 95% by looking at imaging. Now, that being said, you know, you can say all kinds of crazy things in filings in the SEC, and it's there's this whole startup thing, but University of Louisville is a really good, you know, medical, a medical university. There might be some technology that maybe might translate into, at least from a diagnostics perspective, a very accessible supplement, at least for at the beginning, supplement to the existing di existing diagnosis, diagnostic uh processes that we have today.
SPEAKER_01But it would make the insurers feel a whole lot better if they could just say, oh, we know MRIs, we know this, we know technology to say, so the psychologist says this, but also the MRI also says this.
SPEAKER_03And it should be there. That correlate theoretically should be there, right? The the reason that I became so interested in ABA treatment is the idea of plasticity, the idea that by experience these brains are being rewired in a sense. So the idea that we could identify the wiring and then go the other direction, I mean, that seems that seems plausible. You know, it's there. And hopefully that technology that you're talking about out of the University of Louisville is, you know, something that will come into practice or that will be fruitful because there are a million, well, I don't know about a million, there are many different brain-based markers that could easily, even a functional MRI that could easily distinguish, you know, an uh control brain from an autistic brain, to use that language specifically.
SPEAKER_03And then how that translates into somebody's interaction with their behavior at home, school, or otherwise is still an open question. So I mean, again, I think these are really noble efforts. It would bridge the gap between the language that we're speaking and what the medical table's been chewing on for all these years. And yeah, I hope we do find something. I'm glad that there's still people out there, and I'm sure there will be ongoing putting forth that noble effort. That's great.
SPEAKER_00That was always your jam for sure.
SPEAKER_03Yeah, I mean, I I really appreciate having that knowledge base in terms of brain and behavior and it and and then my developmental framework, it kind of all fits nicely into this, you know, question of uh staying away from the idea of normalizing something as opposed to uh allowing something to be significantly functional in their environment or person in this case. Uh yeah, it's interesting for sure.
SPEAKER_00Go ahead. Anything you wanted to add on that before I had a different question for you, Chris?
SPEAKER_01No, I'm good.
SPEAKER_00Okay. So are you familiar? And I'm not even that familiar. I happen to see it on a Facebook post and looked into it a little bit with the uh RBT strike going on in Maryland right now. So let me open this up to you. So I happen to just look at the literally a Facebook post that had people like picketing. And my first thought was good for them. I can speak for Mike and myself. We've both been, well, I've been in RBT. Mike currently does a lot of direct work with clients, and we've made it a core value to value the RBT.
SPEAKER_00That's literally one of our tenants of Ascend Behavioral Solutions. And I know a lot of companies say that. So people will probably hear and be like, yeah, so does everyone else. And maybe maybe that's true. But we've really tried to and continue to try. And our turnover rate, I think, shows that we value the RBT because at the end of the day, we feel like they're the most underappreciated and probably the most, if not very close with the BCBA important person because they're the people that when people think of ABA, they think of you know autism treatment, and it's typically done by the RBT.
SPEAKER_00So my first thought was good for them. And that's still my prevailing thought. I told it, I sent it in a chat with a buddy who owns a business. And I think he, I don't know if he was being sarcastic or not, but he was like, wonder what their reimbursement rates are. So I was like, huh, I didn't even think about that. So I was like, okay, so now there's you know two kinds of thoughts. My initial thought of like people making money or getting rich on the backs of RBTs that need to be treated better. And then the other thought of, well, I wonder what their margins are and if that's actually the case.
SPEAKER_00You probably know way more about this whole situation. So I just wanted to open it up to you. What are your what's going on in this situation? What are your thoughts? What are you hearing? Maybe how does it how is this a microcosm of a larger issue in the field? The floor is yours on that, Chris.
SPEAKER_01So I'll very briefly I'm gonna I'm gonna touch to the like big picture stuff, jump to the specifics and then jump back to the big picture. So yeah, big picture, you highlighted the tension, like one of the fundamental tensions of the industry that I had thought was just kind of like fixed and static, and it was always going to be there. And it was going to be this role that exists in autism therapy of the RBT, that because of the structures that exist, is not unless there is a very special organization out there with a very special arrangement with its payers, that role is not going to be paid very well ever.
SPEAKER_01Ever. Because the way that it is structured, that is somebody who, in terms of like degrees, certifications, and whatnot, does not get respected by the system. You really don't you really don't exist or matter in a very potent or powerful way in American healthcare, especially one that involves third-party payers, unless you have a master's degree or a doctorate, or you know, you know, or you know, PhD, like kind of that kind of equivalent. So I always thought that this was just kind of always going to be there. It's always gonna be high turnover, it's gonna be difficult to, you know, to hire and compete against other types of jobs that have comparable wages in logistics and food services and retail.
SPEAKER_01But I think that the world that we're living in right now, and this actually goes back to the social media world that we live in, to where everybody's got to be on a side, good or bad, this fixture of the industry is probably going to become a lot more kinetic than we've seen it before. Now, it's so so what we're looking at there is a company called Verbal Beginnings that was founded, I'm gonna say circa 20, 2004, by two BCBAs. I'm gonna space on their names right now, but Verbal Beginnings is based in Maryland and is still owned by these two BCAs, BCBAs that started it, and that kind of creates the first quirk or wrinkle that I find really interesting in the situation.
SPEAKER_01That the first meaningful strike activity that I've ever observed in the autism therapy industry didn't happen at a private equity-backed, like mega company. It happened at this sizable, privately held, but like still for like in in terms of things. I think they had like nine clinics, maybe seven. I think no, they have seven clinics and two more on the way when this was happening, all kind of in the in the DMV. So they're not like masters of the universe of the industry, and yet this is where this initial flashpoint happened. So that's those are just facts, and then my old observation on those facts.
SPEAKER_00Told you even more about it than I did.
SPEAKER_01Yeah, so I have I have spoken with I've spoken with folks at the union, I've spoken spoken with one person at the that's on the picket line, and their bottom line is that is their personal bottom lines. They feel like they're not getting paid nearly enough for the level of work and the level of skill that they have to bring to that. Now, in apparently in their company, there are people that are doing that work that do have master's degrees, but they're still getting RBT level wages. And even people that have been RBTs for a while bring an incredible amount of talent, you know.
SPEAKER_01In in I'd say like maybe only in the absence of like education, just because like they don't have they don't have master's degrees, and I have a bachelor's degree. That doesn't mean that they're really freaking good at their job, right? So at the bottom line where everything kind of comes back to is they just want to get paid what they think they're worth. They want living wages so that at the end of the day, they can come into work every day with at least one less thing to worry about. Now that's their, you know, that's that's like their their key line. They also have they also have some complaints about how the company is is trying to handle how they deal with this pledge that they had set themselves up with to give RBTs a guaranteed 40 hours of 40 hours of work every week.
SPEAKER_01There are some issues and some complaints about how supplies are handled in each of the clinics. Like they'll be running out of supplies and like they don't feel like management's really doing anything, anything to make sure that they have the the tools and supplies that they have to do their jobs. The unionization of that group is really new. They had their vote on May 1st. The vote was 33 33 to 1 in affirmation of unionization. They got the Teamsters to rep them. No, let me say, let me take that back. I want to say Yeah, so anyway, they brought the Teamsters in.
SPEAKER_01They've what they've been working on is their first collective bargaining agreement. And part of the strike is the breakdown, what they see as a breakdown in that collective bargaining agreement effort to try to get to the place where the wages are going to be for the RBTs that they feel like are actual living wages for the Maryland area.
SPEAKER_00Which which is interesting, right? Because you've got two again, two different things. So a living wage isn't necessarily correlative to the reimbursement rate, right? And we see that in in California, like some of the wages that we get offered are just absolute crap. And the minimum wage in San Diego, do you remember what it is? I think it's like in the 18 or it's about to be 20 bucks an hour, right? And like the the margins are are tricky.
SPEAKER_00So yeah, I mean, what where does that leave people? And you as an investigative journalist probably know, like you've got those two things which are related but aren't necessarily the same things. You've got the margins or the reimbursement rates, and then you've got the the living wage. It's like, well, I want to try to provide you with a living wage, but if I can't sustain the business, then we can't provide you with a living wage. What are what are you seeing kind of on that front?
SPEAKER_01I mean, that is the question, isn't it? It's like what is a comp what what is a company to do? And I mean, yeah, I don't want to frame that question up as it is special or unique to places where there is tangible friction between the labor of that organization. Because that again, like that's the fundamental tension within the business aspect and to and to some lesser degree, much less forgive, I would actually argue, the tension that there is between the RBT role and the rest of the universe in which it exists. So one of the so one of the things that you know I think is going to kind of play out, like I think they're probably gonna they're probably gonna get to an agreement.
SPEAKER_01These people are probably gonna want to keep their jobs. The the employers are probably gonna want to make sure that they bring some of these people back because it would be just absolutely destructive to try to replace 33 staff members. Um and they'll get they'll find their accord. I I have some I have some degree of confidence that they'll get there, and I think that they will, because at the end of the day, if they don't get to it, like nobody's getting paid, no work is getting done, and it's a bad situation for literally everybody. But this tension within the industry when it comes to RBTs has been this kind of quiet malcontent that has been there for a very, very long time.
SPEAKER_01And it's uh and it's so profound as to be influenced by a part of the structure that is almost impossible to change, and that is what do you get paid in the fee schedule? The the the solution to that problem is one that is actually outside of the control of largely outside of the control of the ABA provider. Because who sets that fee schedule? It sure as heck isn't you guys, it's the payers. Now, one of my like kind of weird or like shower thoughts on this is like I think there is more of an existential question about the role of RBTs than than it is for anything else in in the industry.
SPEAKER_01Like, I understand why the RBT role exists. BCBAs can't be everywhere at once, and it is very effective and very possible to train people in certain protocols to do good in the life of a child. But if you can't pay them and they're and there is this malcontent that has just been brewing under the surface forever, something's gotta give. And it's not going to it's not gonna be the total existence of the industry, like the industry is too important for that, it's too big for that. What's going to give is that the RBT role becomes significantly diminished or even goes away in some circumstances because it cannot be effectively provided in a way that's happen that's good for anybody.
SPEAKER_01The high turnover rates that we see are bad for everybody are bad for everybody. Like I'm gonna pull the central reaches survey numbers, where like medians are like 90%, like annual turnover in RBT groups, like a normal, like median is like 80%, 90%, and then bad in bad circumstances in the highest, it's like 110% turnover rate in a year. So it's bad. It's bad. So like that's bad for everybody. That's bad for the RBTs, it's bad for the kids, it's bad for the providers. So like terrible there, nobody is well served or happy with how we conceptualize RBTs today. And I thought it was just kind of stuck, gonna be stuck in and in that kind of stasis all always and forever.
SPEAKER_01But the verbal beginning strike shows us that this could be very kinetic very quickly because of just how long this malcontent has existed, and no one really has no one in the industry for sure at least has the ability to fundamentally fix it.
SPEAKER_00Well, this is where I really like appreciate your objectivity, and I think you're selling yourself short on a lot of things because like I run parent groups, right? And I'm not a parent, and I constantly say, Well, I can't understand as a parent, but sometimes there's a benefit being objective and just being able, that's kind of the whole point of our field is to get into somebody's home and be an objective observer. And I think that really gives you a unique ability because a lot of times when you're in the field, it's just like this is how we're doing it. So let's figure out the way to maximize it. And sometimes people out of the field can be like, is this even the best way to do to get the services rendered?
SPEAKER_00And we do a lot of BCBA direct. We've always wondered, like, well, the RBT makes sense if you're doing 40 hours a week or even 25 hours a week, but what if you're only doing two or four hours a week? Can you just have the BCBA do that directly? So I think you're selling yourself short there. And I really, actually, really appreciate your perspective. I agree with it wholeheartedly that that that RBT position is interesting. Cause I mean, I think we as well as a lot of other business owners that know, we pay about like 50% of our reimbursement rate back to the RBT.
SPEAKER_00And you might be like, oh my God, well, aren't you aren't you just making bank? Because off every hour build, you get 50%. But the like we talked about earlier, the pairs require so much we need uh practice management, we need building software, we need note-taking software, we need Microsoft Word, we need all sorts of things. So it's like, yeah, I mean, those those margins, which aren't that big to begin with, you know, 50%, but 50% of not a super high number gets smaller and smaller and smaller as we try to make sure that we can meet all of the insurance requirements.
SPEAKER_00And then we run into a situation where are we sustainable as an organization to pay these people what they truly deserve to be paid? Because, like you said, they are special individuals. So yeah, I think maybe systematically that that does beg the question of how is this most effectively delivered to the consumer.
SPEAKER_01And there's one other, you know, I want to bring back the the point that that that Mike has has brought up a couple times when it comes to the impact on culture, the role culture plays in a lot of what we're talking about. And we as Americans have a pretty, I'm gonna say it like on the whole, like collectively in the median, we have a pretty, I frankly think a pretty poor culture when it comes to family cohesion generally. Not to like wax too like too specifically on that, but in the context of what we're what we're talking about here, the collective system has told parents we're gonna offload the the training treatments, the protocols that help maximize the potential of your child onto an exclusively a provider, despite the fact that mom and dad live with this person all the time.
SPEAKER_01Right. So because of just the way that the model is set up, we turn to clinic we turn to clinicians to fix all of our problems when the reality might be that when it comes to the special circumstances that define the the unique and wonderful aspects of the autism therapy industry, it actually needs to be a a practice in a field that is heavily oriented towards the training of family members. Now that it opens up a whole other can a whole other can of worms, right? Let's like one of the and actually bring like Mike talked about the power of the federal government will bring back like you know, personal care like as a as a field is also getting a lot of scrutiny because in some places you can get paid by Medicaid to be the caretaker of the person of a vulnerable person in your charge.
SPEAKER_01You know, that brings up all kinds of questions on whether or not that's appropriate, whether or not that's something that the government should be covering or paying for, both ways, both in the affirmative and the negative. But then there's a whole slate of questions culturally, but also from a business perspective that need to be figured out when it's time when there is this potential solution that requires potentially unpaid labor on behalf of somebody else and who really reaps the benefit of that of that parent of that parent training, right? To some degree, yeah, you kind of offload that work onto a parent by not having an RBT that you have to pay, and that redounds for the financial benefit of an ABA provider, whereas all of a sudden, if they're billing for I don't know what I don't know what don't know what the numbers are specifically on the on the mains for you know what your codes look like for like BCBA direct care or like the group things like that.
SPEAKER_01But if you're not having to worry about the overhead of having to pay a whole bunch of our RBTs and you're able to maybe maximize your time for potentially more valuable BCBA time because you have all of your parents acting as live in RBTs, what do we do about the financial benefit for the corporation there? Or even if it's a nonprofit that's doing that still a financial benefit to them that does need to be considered. How does it how? I have no idea. But like you do need to recognize that in a parent-trained and a parent-heavy model, that's uncompensated work.
SPEAKER_01That redounds to the financial benefit of the system. And I don't, again, I don't know what to do with that. You know, I'm sure there's people that have thought a lot about, you know, how that works. I'm just not, unfortunately, one of those people and I don't know them yet.
SPEAKER_03I like the uh theme of uncompensated work. I think that's an important topic here for a second. So one of those features that you alluded to, one of those jobs that you alluded to, Dan, is sitting on hold for four hours to discuss two rejected claims at most, because You'll have to hang up and get back on. Which speaks to the volume of need and work and all those other things will just chalk up to bureaucracy.
SPEAKER_00Driving to the client's house.
SPEAKER_03Although that's that's huge. That's very unique to us in healthcare. Well, maybe not very unique to us. I'm sure there's PTs, OTs that do that rehabilitative care too, and have to move around, but that is quite an overhead cost. And then there's this beautiful phrase that we like to throw around in our treatment plans, which goes largely uncompensated. This thing called collaborative treatment. And one of the folks that's supposed to be in there is the pediatrician, right? Now I'm pretty sure they have a code to get reimbursed for that treatment. We don't, right?
SPEAKER_03I uh you wrote an article on this recently, and I love the I believe the title at the end was It's Not That Simple, which I thought was perfectly encapsulated. Tell us as much as you can about what you learned on that journey. Because yes, so we we like to talk, uh, you may have heard it, we like to talk the idea of some future where there's a true integration between behavior and pediatrics. Pediatricians deal with all sorts of questions like kids peeing in their beds at night beyond the age you think they should, peek at eating, sibling rivalry, the hyperkinetic motion before there's ADHD, you're hyperkinetic.
SPEAKER_03These are all things that can now, we could probably help with on the front end, or at least differentiate that. That'd be another way to collaborate, which there isn't even a treatment model proposed, as far as I know right now, with regard to insurance payers. Tell us a little bit more about that idea of collaboration with, say, pediatricians and then in general from your perspective with ABA. Because it would be a beautiful thing to be able to compensate and be able to achieve truthfully.
SPEAKER_01It would be. And just you know, to start, at least at the front and to start positive, there is a precedent for models like that. So there's the collaborative care model, COC, that exists in Medicare. No, so in Medicare, yeah. So it comes down from Medicare that includes codes and billing, and some that's starting to make its way through private health plans where you're integrating, you're integrating a system that includes a psychiatrist that works on kind of like a case management basis, someone who's more like a therapist that has a bit more FaceTime with the uh with the patient, and then of course the other side of that triangle being the the the physical healthcare provider, the doctor, or the like the nursing equivalent.
SPEAKER_01We could do that. I'm only saying we just because it's you, you three of us, the three of us talking about it.
SPEAKER_03We appreciate that. I appreciate that.
SPEAKER_01Yeah, the the autism therapy industry could do that, but it's going to take a lot of enterprising individuals to develop and validate models that look exactly like you. You can't just copy and paste that stuff. All behavioral health is too unique just to simply you know follow, you know, in the perfect follow perfectly in the footsteps left in the snow of some other part of the healthcare industry. Now, the problem is that nobody has a great incentive to own the collaboration problem. Yes, pediatricians can bill for that time, but I don't know if that's like the time that's what they want to be billing that time for that time.
SPEAKER_01Do they have it?
SPEAKER_02Yeah.
SPEAKER_01Yeah, put the if do they have the time, put the human thing away. Like, do they feel like they can, like, or they even want to? Do they have an interest in this? Do they do they have a financial incentive? Like, is it worth their time to do it? So even though, yeah, so excellent observation that they do have a better like financial incentive to do this than the B than the BCBA world or the other mental health providers that can do this, but nobody really does. No one has a really great incentive to do it other than you know, other than the things that we know are important that we can articulate outside of healthcare, and that is the ennoblement of humanity.
SPEAKER_01Like that's that's kind of why we're all we're all here to some degree, but it's just that the system doesn't necessarily respect that. Now, there are people that are trying to the autism therapy industry, like one of my one of my theses is that this entire industry is trying to do more all the time. You're seeing a lot more providers that are integrating, you know, physical therapy, feeding therapies, occupational therapy, mental health services, that they're they're trying to do more, but they're trying to do more in the kind of with the cousins of the family that they know really well. And there needs to be like big structural changes that will make financially viable a true integration between physical health care and and and ABA.
SPEAKER_01The closest thing that I can see in the industry right now are probably some academic systems that just happen to have a really strong research component that is related to autism and autism therapy. So, like maybe Beerman, like you know, there are affiliations with the universities like down there. Funny enough, in San Diego, there's a company called Cortica that includes all kinds of physical health care specialties, but they do not translate, nor do they ever intend to step over into the primary care element.
SPEAKER_01So while you can get physician access to specialist care at a company like that, you're still not going to be able to have a true unification uh with the with the with the physical healthcare provider. Now, do you always need to have that perfect unity where it's like literally one organization? No, collaboration happens all the time in healthcare. Healthcare is kind does they they try it and it's known for it. Is it always successful? No. But like the best of intentions in healthcare are always found in the collaborative models. And there's maybe there is something there where you have a company that can take on as much as possible when it comes to the doctorate level specialized care.
SPEAKER_01And that way the pediatrician can just kind of worry about, can just kind of worry about certain medications. They can like worry about the sniffles and the antibiotics, they can worry about the broken arm as opposed to having to take on worries that are related to their sleep disturbances or their digestive issues, things like that.
SPEAKER_03Yeah, no, they and they don't. I think you make the best point at the beginning there, they don't have time for that. Uh, they may or may not have some subspecialty or training in that and speaking of pediatricians here, but they don't. So I just want to say it here again. We will be parked down the hall from that pediatrician's office in some future, because I do think that that integration would would be revolutionary for sure. Certainly not rushing any of us. We are approaching our two-hour mark, gentlemen. So if there's anything you wanted to say, say it now, or we might have to wait for the next time.
SPEAKER_00I have one quick question. No, go right ahead. We got plenty of time. You've spent some time on the opiate epidemic and that side of things, correct, Chris? So I was thinking about this the other day, actually, as I was at my doctor's office thinking about getting some uh medication and or asking about some medication. And the opiate uh opiates somehow just popped into my brain when I was thinking about it. And I was thinking that like people that might have gotten them initially went in and expressed some level of pain and were expressing some level of the pain going away when they had the opiates.
SPEAKER_00And based on like we were talking about being able to objectively measure things, my guess is it's pretty challenging to objectively measure pain. It still came back to patient report. And obviously, you know that we know that there can be biases or things like that. And I think a lot of times doctors are, you know, judged like, well, why were you giving this person? But they were coming in and saying they had pain and they were saying that it went away, and maybe this was the best, you know, protocol, protocol that they had. And it even kind of relates to what we were talking about earlier with, you know, ABA and that that treatment, because we don't have like a you know brain scan to say, like, oh, your pain's decrease as much because I can show I can show it on a scale that you gave me, but I can't show it on a machine.
SPEAKER_00So what kind of stuff did you run into like that? Like with like spe speak a little bit on that because I'm sure you have a wealth of knowledge. Like, I don't even know what doctors were supposed to do in that situation, but I know it led to a lot of lawsuits and a lot to a lot of people that you know had yeah, over over-prescribed were probably then addicted. Maybe, maybe the government did the pendulum right and then said we're not gonna prescribe it. So then they went to illegal substances, which you know created a whole thing. But I was just sitting in the doctor's office.
SPEAKER_00I was like, I wonder what what we should do, what we could, what was the other option? So I don't know. That's my only question. My last question to you, Chris. What are your thoughts on any of that stuff?
SPEAKER_01Yeah, so when it comes to uh when it comes to you know opioids and opiates, that the whole story and the the 20 to 25 year history of that is absolutely rife with genuine outright fraud and malfeasance by people who are gen that were genuinely bad, loose structural systems, like the federal government, like is like I ultimately lay a lot of the responsibility for the scale of the problem at the feet of the federal government who failed to conceptualize the amount of bad that and the amount of evil that people were willing to go to to create wholesale frauds to just flood the communities that were most hit by this with illicit prescription pain pills.
SPEAKER_01I'll also lay a ton of blame at the feet of you know, of the of the pillmakers who knew very well that these opioids were addictive, that they do create incredible amounts of cravings that all the technologies, well, I mean, a coding on a pill, you call that technology as much as you want. But like all of their efforts to try to make it so that you can't abuse these pills, they all fell so so f hard on their faces to be laughable. Um I uh I am so grateful that there's honestly is not a great corollary between what we're seeing today in autism, as we saw with the with the opioids, because a child's not gonna overdose and die on ABA.
SPEAKER_01Now, pain is pain, trauma is trauma. People who are getting ABA that shouldn't be that maybe are manifesting symptoms that are more related to trauma are just gonna be re-traumatized if they're gonna be put into a place where their behavioral health intervention is not right and for them, but they do get to live, they get to have a life. So, you know, uh I think there's some there's interesting structural comparisons between the two, and then a lot of those don't necessarily fall to the like provider level as much. Like, and there's also a ton of like corrupt doctors that led to a lot of that.
SPEAKER_01But even even though like the most shisty and like bad ABA providers are never going to produce a product that is going to lead to somebody overdosing on it and dying or leading to a life of addiction. Now it might lead to a life of anxiety, of disassociation from one's body, and it might lead to some things, but it's still it's still not it's still not a corollary, and it's frankly inappropriate to try to compare like try to compare like from an anti-ABA perspective this to the opioid epidemic.
SPEAKER_01You know the industry that that as we see it today is one that suffers from misunderstanding like all around, but they're they're not at all the same. And one of the things that I I I pull to you know that I I like to pull from when I'm thinking about when I'm thinking about the industry like all the industries that I cover. So yeah, I cover I still cover a lot of the addiction treatment industry. I'm not writing necessarily about the opioid crisis, like really frankly at all recently. I write about also psychiatric hospitals.
SPEAKER_01I write a lot about you know, obviously I write a lot about autism therapy. And there's always there's always going to be potential for abuse in all of those settings because fundamentally we deal the the industry deals with people at their most vulnerable moments in a way that I think is frankly a little unique and unlike say the hospital or physical healthcare system, and yet the system has existed to some degree of success because of the remarkable morality of the people that make it happen. So you know when I'm thinking of when I'm thinking about these two these two kind of disparate industries, you know, we can actually probably s be grateful that ABA doesn't have the pill, a pill, because there is if there's no destructive device in a system that the destruction that device would wreak upon a system just simply can't can't happen.
SPEAKER_01It doesn't exist. Like nothing comes from nothing. So yeah, I don't I don't think I've really successfully reached the point in the answer that that you're articulating, Dan. But you know, when when putting these two together ideas together in my head, that's where I land.
SPEAKER_00Yeah, it wasn't even articulate. I was just like pondering. I was like, man, I I was kind of just feeling bad for the doctors when I was in there. Like what what were they supposed to do? Like, how do they how do they know if they if that person actually needs the opiate or not? Like there's not like a a way to think about it. Mike, I don't know if you have anything you wanted to because I know you did want to open up that.
SPEAKER_03Well, we we talked a little bit at the beginning now. I mean, I think this is a that was a good, it was a great response there. I appreciate you you keep uh reiterating, you know, you're not sure if you answered our question. And I think it it speaks to the perpetuity of your investigative drive. And I'm sure you've got to preserve that as a journalist. So every time you say that, it's like, well, you did answer the question, and then I was reminded, well, he could probably investigate a little further or ask some more questions about it. So we are grateful, sir, that you are doing that in our space, that you're talking about the business that illuminates a lot of inevitably there, you know, the the the business and the practice have to have a strong relationship.
SPEAKER_03We like to favor the practice over the business, but we can't survive without the business and the solvency. So we are ever grateful that you're out there investigating these pieces, talking to people, and certainly very grateful for your insights today and for your time. Any so people can find you at BH Business. You've got a slew of articles on there. I I found you under the autism IDD treatment link. Is there any others that you want to plug there or any other areas that you're writing on under that drop-down?
SPEAKER_01Yeah, so I mean, BH Behavior Health Business is myself, Laura Lovett, who is the managing editor, and Ashley Hollowell, who is a who's also who's a reporter and also writes for us well. So it's just the three of us working. So all of you cover everything on there. We cover everything. So you'll find me there. And if you want to tell me to my face what you really think about this conversation, you can actually catch up with me at the Autism Investor Summit East. So we'll be in DC in in November. So if you want to, if you want to come, if you want to, if you want to say, hey, you know, shake my hand, spit my eye, whatever, uh, you know, that's that's a place for sure that you can do that.
SPEAKER_01And you can find all that information on our website.
SPEAKER_03We will have to sit down for a drink or a meal, I think. Uh, better yet. Better yet. Sir, we cannot thank you enough for your time. Anything ever that ABA on tap can uh do for you. We're gonna give you an open invitation. Whenever you want to come back, you just let us know.
SPEAKER_00We hope very much hope you'll be coming back on so that you can share some of the current events and things like that. We'd love to have you on again, Chris.
SPEAKER_01Yeah, I I am flattered by the offer, and I'll I'll probably take that step on at some point.
SPEAKER_03We are very grateful for the connection and uh we will maintain it. So, Dan, I've been enthralled. I failed to do my my gems. You what do you have? Oh man, I've always got my our closing our closing key points before our our tagline. I'm gonna ask for your help here. Some Chris, help us out here too.
SPEAKER_00So it's not necessarily PE. The BCBAs can look at themselves in the mirrors to be more ethical.
SPEAKER_03We all agree that this is built on the backs of the RBT.
SPEAKER_00Yep.
SPEAKER_03All right, what else do we learn today? Oh man, we learned collaborative treatment. It's a good tagline. Collaborative treatment. Not that simple.
SPEAKER_00Not that simple. And always analyze for oh goodness.
SPEAKER_03I was gonna say stay ethical. I think that's what Chris kept going back to. There's a lot of value in staying true to who we are and keeping our ethical wits about us and always analyze responsibly. Thank you, sir. Great to see you. Good to see you guys.
SPEAKER_00Always analyze responsibly.
SPEAKER_02ABA on tab is recorded live and unfiltered. We're done for today. You don't have to go home, but you can't stay here. See you next time.
Send us Fan Mail ABA on Tap is proud to present Richard Wagner (Part 2 of 2): One tiny checkbox can be the difference between a clean claim and a full-blown payer denial, and most ABA clinicians only find out after the...
Send us Fan Mail ABA on Tap is proud to present Richard Wagner (Part 1 of 2): If your ABA tech stack feels like it was built for billers instead of clinicians, you’re not imagining it. ABA onTap sits down to brew with...
Send us Fan Mail ABA on Tap is proud to present CartNarcs Special Agent Sebastian Davis (Part 2 of 2): A stray shopping cart is never just a cart. It’s a tiny decision with outsized ripple effects, and it can tell you a...
Send us Fan Mail ABA on Tap is proud to present CartNarcs Special Agent Sebastian Davis (Part 1 of 2): A stray shopping cart can scratch paint, block a space, and ruin somebody’s day, but the bigger story is what...
Send us Fan Mail ABA on Tap continues the brew with Holly Blais (Part 2 of 2): A school can be loud with “problems” and still be full of useful information, if you know how to listen. ABA on Tap resumes their chat with...